Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Shares Issued (2023 - 2025)

Indivior Pharmaceuticals has reported Shares Issued over the past 3 years, most recently at $1.0 million for Q3 2025.

  • For Q3 2025, Shares Issued changed 0.0% year-over-year to $1.0 million; the TTM value through Mar 2026 reached $1.0 million, down 50.0%, while the annual FY2025 figure was $2.0 million, 33.33% down from the prior year.
  • Shares Issued for Q3 2025 was $1.0 million at Indivior Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • Over five years, Shares Issued peaked at $2.0 million in Q1 2023 and troughed at -$1.0 million in Q4 2023.
  • A 3-year average of $1.1 million and a median of $1.0 million in 2024 define the central range for Shares Issued.
  • On a YoY basis, Shares Issued climbed as much as 0.0% in 2024 and fell as far as 50.0% in 2024.
  • Year by year, Shares Issued stood at -$1.0 million in 2023, then surged by 200.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Business Quant data shows Shares Issued for INDV at $1.0 million in Q3 2025, $1.0 million in Q1 2025, and $1.0 million in Q3 2024.